Learn More
PURPOSE Older adults are vulnerable to chemotherapy toxicity; however, there are limited data to identify those at risk. The goals of this study are to identify risk factors for chemotherapy toxicity in older adults and develop a risk stratification schema for chemotherapy toxicity. PATIENTS AND METHODS Patients age ≥ 65 years with cancer from seven(More)
INTRODUCTION This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission tomography (PET) scans of the brain(More)
OBJECTIVES To evaluate the prevalence of polypharmacy and potentially inappropriate medication (PIM) use and the association between these and chemotherapy-related adverse events in older adults with cancer undergoing chemotherapy. DESIGN Secondary analysis of prospectively collected data. SETTING Outpatient oncology clinics in seven academic medical(More)
BACKGROUND Bevacizumab leads to improved survival for patients with metastatic colorectal cancer (CRC) or non-small cell lung cancer (NSCLC) when added to chemotherapy. Little is known about factors associated with receipt of bevacizumab, or whether bevacizamab is associated with increased toxicity when added to chemotherapy. PATIENTS AND METHODS We(More)
PURPOSE This study evaluated age-related changes in pharmacokinetic and pharmacodynamic parameters of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in patients with metastatic breast cancer. METHODS Forty patients received nab-paclitaxel (100 mg/m(2) weekly for 3 weeks followed by a 1-week break) as first- or second-line chemotherapy. Blood(More)
BACKGROUND Older adults with cancer are vulnerable to functional decline, which places greater onus on caregivers. Few studies have prospectively examined burden in caregivers of older cancer patients. The objective of this study was to determine the factors associated with high caregiver burden. METHODS In total, 100 caregivers of patients aged ≥65 years(More)
BACKGROUND Little is known about complementary medication use among older adults with cancer, particularly those who are receiving chemotherapy. The objective of this study was to evaluate the prevalence of complementary medication use and to identify the factors associated with its use among older adults with cancer. METHODS The prevalence of(More)
e19501 Background: Polypharmacy and potentially inappropriate medication (PIM) use are common among older adults. The goals of this study were: 1) to evaluate the prevalence of polypharmacy and PIM use and 2) to determine the relationship between polypharmacy and PIM use with chemotherapy-related toxicity (tox) in an outpatient population of older adults(More)
9037 Background: Oncologists may empirically reduce chemo doses with the 1st cycle (PDR) presumably to minimize tox. We studied the factors associated with PDR in pts > age 65 with advanced CA receiving chemo with palliative intent and evaluated the association of PDR with tox outcomes. METHODS This is a secondary data analysis of a multi-site prospective(More)
OBJECTIVE In older men with prostate cancer, aging is associated with reduced anxiety and increased depression. The purpose of this study was to examine the association among age, anxiety, and depression in a cohort of older adults receiving chemotherapy. METHODS This is a secondary analysis of a prospective longitudinal study investigating chemotherapy(More)